Form 8-K - Current report:
SEC Accession No. 0001558370-21-008482
Filing Date
2021-06-21
Accepted
2021-06-21 17:29:13
Documents
13
Period of Report
2021-06-16
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tgtx-20210616x8k.htm   iXBRL 8-K 53401
2 EX-3.1 tgtx-20210616xex3d1.htm EX-3.1 10988
  Complete submission text file 0001558370-21-008482.txt   194032

Data Files

Seq Description Document Type Size
3 EX-101.SCH tgtx-20210616.xsd EX-101.SCH 2698
4 EX-101.LAB tgtx-20210616_lab.xml EX-101.LAB 16831
5 EX-101.PRE tgtx-20210616_pre.xml EX-101.PRE 11597
6 EXTRACTED XBRL INSTANCE DOCUMENT tgtx-20210616x8k_htm.xml XML 5017
Mailing Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 (212) 554-4484
TG THERAPEUTICS, INC. (Filer) CIK: 0001001316 (see all company filings)

EIN.: 363898269 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32639 | Film No.: 211032079
SIC: 2834 Pharmaceutical Preparations